HER2 Support Group Forums - View Single Post - Happy New Year--a new and promising oral drug which crosses the blood brain barrier

Lani · 12-29-2007, 11:07 PM

and targets multiple members of the her family is being developed with promising results:

Mol Pharmacol. 2007 Nov 1 [Epub ahead of print] Links
Cellular and in vivo activity of JNJ-28871063: a non-quinazoline pan-ErbB kinase inhibitor that crosses the blood brain barrier and displays efficacy against intracranial tumors.

Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
Bristol-Myers Squibb.
JNJ-28871063 is a potent and highly selective pan-ErbB kinase inhibitor from a novel aminopyrimidine oxime structural class that blocks the proliferation of epidermal growth factor receptor (EGFR; ErbB1) and ErbB2 overexpressing cells but does not affect the growth of non-ErbB overexpressing cells. Treatment of human cancer cells with JNJ-28871063 inhibited phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2 and blocked downstream signal transduction pathways responsible for proliferation and survival. A single dose of compound reduced phosphorylation of ErbB2 receptors in tumor bearing mice, demonstrating target suppression in vivo. Tissue distribution studies show that JNJ-28871063 crosses the blood brain barrier and penetrates into tumors where it is able to accumulate to higher levels than those found in the plasma. JNJ-28871063 showed oral antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2. In an intracranial ErbB2 overexpressing tumor model, JNJ-28871063 extended survival relative to untreated animals. The brain is a primary site of metastasis for EGFR overexpressing lung cancers and ErbB2 overexpressing breast cancers. Therefore, the ability to penetrate into the brain could be an advantage over existing therapies such as trastuzumab (Herceptin) and cetuximab (Erbitux), which are antibodies and do not cross the blood brain barrier. These results show that JNJ-28871063 is orally bioavailable, has activity against EGFR and ErbB2-dependent tumor xenografts, and can penetrate into the brain and inhibit ErbB2 overexpressing tumor growth.
PMID: 17975007 [PubMed - as supplied by publisher]

12-29-2007, 11:07 PM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	Happy New Year--a new and promising oral drug which crosses the blood brain barrier and targets multiple members of the her family is being developed with promising results: Mol Pharmacol. 2007 Nov 1 [Epub ahead of print] Links Cellular and in vivo activity of JNJ-28871063: a non-quinazoline pan-ErbB kinase inhibitor that crosses the blood brain barrier and displays efficacy against intracranial tumors. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM. Bristol-Myers Squibb. JNJ-28871063 is a potent and highly selective pan-ErbB kinase inhibitor from a novel aminopyrimidine oxime structural class that blocks the proliferation of epidermal growth factor receptor (EGFR; ErbB1) and ErbB2 overexpressing cells but does not affect the growth of non-ErbB overexpressing cells. Treatment of human cancer cells with JNJ-28871063 inhibited phosphorylation of functionally important tyrosine residues in both EGFR and ErbB2 and blocked downstream signal transduction pathways responsible for proliferation and survival. A single dose of compound reduced phosphorylation of ErbB2 receptors in tumor bearing mice, demonstrating target suppression in vivo. Tissue distribution studies show that JNJ-28871063 crosses the blood brain barrier and penetrates into tumors where it is able to accumulate to higher levels than those found in the plasma. JNJ-28871063 showed oral antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2. In an intracranial ErbB2 overexpressing tumor model, JNJ-28871063 extended survival relative to untreated animals. The brain is a primary site of metastasis for EGFR overexpressing lung cancers and ErbB2 overexpressing breast cancers. Therefore, the ability to penetrate into the brain could be an advantage over existing therapies such as trastuzumab (Herceptin) and cetuximab (Erbitux), which are antibodies and do not cross the blood brain barrier. These results show that JNJ-28871063 is orally bioavailable, has activity against EGFR and ErbB2-dependent tumor xenografts, and can penetrate into the brain and inhibit ErbB2 overexpressing tumor growth. PMID: 17975007 [PubMed - as supplied by publisher]